Dr Reddy's Laboratories (FRA:RDDA) Research & Development: €232 Mil (TTM As of Mar. 2026)


FRA:RDDA Dr Reddy's Laboratories Ltd FRA:RDDA
91 GF Score
Price €13.20
GF Value €13.78
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Dr Reddy's Laboratories Research & Development?

Dr Reddy's Laboratories FRA:RDDA +3.12% 91 Research & Development is €232 Mil as of Mar. 2026. GuruFocus rates FRA:RDDA with a GF Score™ of 91/100 and a GF Value™ of €13.78 (Fairly Valued). The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Dr Reddy's Laboratories's Research & Development for the three months ended in Mar. 2026 was €51 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was €232 Mil.

Dr Reddy's Laboratories  (FRA:RDDA) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Dr Reddy's Laboratories Research & Development Related Terms

Dr Reddy's Laboratories Research & Development Historical Data

* Premium members only.

The historical data trend for Dr Reddy's Laboratories's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dr Reddy's Laboratories Research & Development Chart

Dr Reddy's Laboratories Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 208.34 220.04 253.47 292.72 224.20

Dr Reddy's Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 77.60 63.04 59.83 58.32 50.91
FRA:RDDA
91GF Score
Dr Reddy's Laboratories Ltd FRA:RDDA
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Dr Reddy's Laboratories Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €232 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €232 Mil mean?
Dr Reddy's Laboratories (FRA:RDDA) has a Research & Development of €232 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Dr Reddy's Laboratories and its competitors.
Is Dr Reddy's Laboratories' Research & Development too high?
Dr Reddy's Laboratories' current Research & Development is €232 Mil. Overall, Dr Reddy's Laboratories has a GF Score™ of 91/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Dr Reddy's Laboratories' Research & Development compare to ZTS?
Dr Reddy's Laboratories' Research & Development of €232 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Dr Reddy's Laboratories and its competitors. Dr Reddy's Laboratories's current Research & Development is €232 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dr Reddy's Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Dr Reddy's Laboratories (FRA:RDDA) is currently considered Fairly Valued. The stock's GF Value™ is €13.78, compared to a current price of €13.20 — trading 4.2% below its estimated fair value. The current Research & Development is €232 Mil. Dr Reddy's Laboratories' overall GF Score™ is 91/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Dr Reddy's Laboratories (FRA:RDDA), the current Research & Development is €232 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Dr Reddy's Laboratories (FRA:RDDA) Overvalued in 2026?

Based on GuruFocus' analysis, Dr Reddy's Laboratories stock appears to be undervalued. The current stock price of €13.20 is trading 4.2% below its estimated GF Value™ of €13.78. GuruFocus considers Dr Reddy's Laboratories to be Fairly Valued.

Key valuation signals for FRA:RDDA:

  • Research & Development: €232 Mil
  • GF Value™: €13.78 vs. price of €13.20 (4.2% below fair value)
  • GF Score™: 91/100 with 5 warning signs

No single metric tells the full story. See the FRA:RDDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Dr Reddy's Laboratories Business Description

Address 8-2-337, Road No. 3, Banjara Hills, Hyderabad, TG, IND, 500 034
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly 40% of its generics sales, with other key markets being India (20%) and Europe (20%). Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.
91GF Score

Get the complete analysis for FRA:RDDA

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€13.20
Price
€13.78
GF Value